110 related articles for article (PubMed ID: 9736424)
1. Treatment with interferon gamma enhances fibrinolysis in systemic sclerosis.
Gluszko P; Undas A; Kwasny B; Musiał J; Szczeklik A
Thromb Res; 1998 Aug; 91(4):203-7. PubMed ID: 9736424
[No Abstract] [Full Text] [Related]
2. Application of interferon-gamma containing gel for local treatment of skin ulcers in autoimmune vasculitides and skin changes in progressive systemic sclerosis.
Arnaudova P; Rashkov R; Tsanev R
J Rheumatol; 1993 Aug; 20(8):1445-6. PubMed ID: 8230042
[No Abstract] [Full Text] [Related]
3. Treatment of systemic sclerosis.
Medsger TA
Curr Opin Rheumatol; 1990 Dec; 2(6):956-9. PubMed ID: 2128028
[No Abstract] [Full Text] [Related]
4. Safety and efficacy of recombinant gamma interferon in the treatment of systemic sclerosis.
Vlachoyiannopoulos PG; Tsifetaki N; Dimitriou I; Galaris D; Papiris SA; Moutsopoulos HM
Ann Rheum Dis; 1996 Oct; 55(10):761-8. PubMed ID: 8984943
[TBL] [Abstract][Full Text] [Related]
5. Systemic scleroderma. Multicenter trial of 1 year of treatment with recombinant interferon gamma.
Hunzelmann N; Anders S; Fierlbeck G; Hein R; Herrmann K; Albrecht M; Bell S; Thur J; Muche R; Adelmann-Grill B; Wehner-Caroli J; Gaus W; Krieg T
Arch Dermatol; 1997 May; 133(5):609-13. PubMed ID: 9158414
[TBL] [Abstract][Full Text] [Related]
6. Increased mitogenic activity of scleroderma serum: inhibitory effect of human recombinant interferon-gamma.
Bryckaert M; Fontenay M; Lioté F; Bellucci S; Carriou R; Tobelem G
Ann Rheum Dis; 1994 Nov; 53(11):776-9. PubMed ID: 7826142
[TBL] [Abstract][Full Text] [Related]
7. Interferon-gamma in the treatment of systemic sclerosis: a randomized controlled multicentre trial.
Grassegger A; Schuler G; Hessenberger G; Walder-Hantich B; Jabkowski J; MacHeiner W; Salmhofer W; Zahel B; Pinter G; Herold M; Klein G; Fritsch PO
Br J Dermatol; 1998 Oct; 139(4):639-48. PubMed ID: 9892907
[TBL] [Abstract][Full Text] [Related]
8. Effects of immunomodulating therapy in systemic sclerosis.
van den Hoogen FH; Boerbooms AM; van de Putte LB
Clin Rheumatol; 1990 Sep; 9(3):319-24. PubMed ID: 2124530
[TBL] [Abstract][Full Text] [Related]
9. Toward rational treatment of scleroderma.
Freundlich B
Hosp Pract (Off Ed); 1993 Sep; 28(9A):8, 13-4. PubMed ID: 8408363
[No Abstract] [Full Text] [Related]
10. Recombinant cytokine treatment for scleroderma. Can the antifibrotic potential of interferon-gamma be realized clinically?
Varga J
Arch Dermatol; 1997 May; 133(5):637-42. PubMed ID: 9158418
[No Abstract] [Full Text] [Related]
11. [Long-term results of the treatment of diffuse systemic scleroderma with interferon-gamma].
Blétry O; Laraki R; Cabane J; Francès C; Piette JC; Soubrier M; Wechsler B; de Gennes C; Valat C; Cosserat J
Rev Med Interne; 1993; 14(10):978. PubMed ID: 8009071
[TBL] [Abstract][Full Text] [Related]
12. Recombinant interferon-gamma in the treatment of systemic sclerosis.
Kahan A; Amor B; Menkes CJ; Strauch G
Am J Med; 1989 Sep; 87(3):273-7. PubMed ID: 2505614
[TBL] [Abstract][Full Text] [Related]
13. Treatment of systemic sclerosis with gamma-interferon.
Hein R; Behr J; Hündgen M; Hunzelmann N; Meurer M; Braun-Falco O; Urbanski A; Krieg T
Br J Dermatol; 1992 May; 126(5):496-501. PubMed ID: 1610690
[TBL] [Abstract][Full Text] [Related]
14. [Systemic sclerosis: drugs and new therapeutic methods].
Skretkowicz K; Waszczykowska E; Dziankowska-Bartkowiak B
Pol Merkur Lekarski; 2003 Sep; 15(87):263-7. PubMed ID: 14679854
[TBL] [Abstract][Full Text] [Related]
15. The fibrinolytic system components are increased in systemic sclerosis and modulated by Alprostadil (alpha1 ciclodestryn).
Bandinelli F; Bartoli F; Perfetto E; Del Rosso A; Moggi-Pignone A; Guiducci S; Cinelli M; Fatini C; Generini S; Gabrielli A; Giacomelli R; Maddali Bongi S; Abbate R; Del Rosso M; Matucci Cerinic M
Clin Exp Rheumatol; 2005; 23(5):671-7. PubMed ID: 16173244
[TBL] [Abstract][Full Text] [Related]
16. [Do the interferons have an antifibrotic action? The internist's point of view].
Blétry O; Somogyi A
Rev Med Interne; 2002 Nov; 23 Suppl 4():511s-515s. PubMed ID: 12481407
[TBL] [Abstract][Full Text] [Related]
17. Chronobiology, fibrinolysis, and systemic sclerosis.
Pignone A; Lombardi A; Cagnoni M; Matucci-Cerinic M; Lotti T
J Am Acad Dermatol; 1994 Aug; 31(2 Pt 1):297-8. PubMed ID: 8040426
[No Abstract] [Full Text] [Related]
18. Gamma interferon administration to patients with atopic dermatitis inhibits fibrinolysis and elevates C1 inhibitor.
Musial J; Gluszko P; Undas A; Mahdi F; Kang S; Szczeklik A; Schmaier AH
Thromb Res; 1998 Mar; 89(6):253-61. PubMed ID: 9669747
[TBL] [Abstract][Full Text] [Related]
19. Treatment of systemic sclerosis with recombinant interferon-gamma. A phase I/II clinical trial.
Freundlich B; Jimenez SA; Steen VD; Medsger TA; Szkolnicki M; Jaffe HS
Arthritis Rheum; 1992 Oct; 35(10):1134-42. PubMed ID: 1418004
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation of sclerosis treatment based on blood circulation or vascular lesions].
Takeda K; Shigemi F; Shiraishi S; Nagai T; Kuwabara A
Nihon Hifuka Gakkai Zasshi; 1977 Nov; 87(12):778-81. PubMed ID: 304924
[No Abstract] [Full Text] [Related]
[Next] [New Search]
